BREAUX PAUL W.

CVNA insider Paul W. Breaux sells 10,000 shares ($4.75M) at $475.00 on back-to-back days; 90d track record at CVNA 100% well-timed

Paul W. Breaux executed 2 separate sales totaling 10,000 shares for $4,750,000.00 on 2025-12-11 and 2025-12-12, reducing his holdings by 12.6%. The transaction price of $475.00 is materially above the current price of $91.14. Breaux's prior trades at CVNA show a 100% well-timed rate on the 2 sales with measurable 90-day outcomes—both declined after he sold. His cross-ticker track record displays 20 prior sells with an average 90-day return of -79.1% and a 90% well-timed rate. The stock is up 38.8% over the last 30 days and 26.0% over 90 days, and the sale occurred while the stock traded near its 52-week high of $94.55 (the transaction price of $475.00 appears to reflect a stock split or other structural event not detailed in the filing).

Paul W. Breaux sold 20,000 shares of CVNA for $8,770,000.00 on 2025-12-08; stock currently at $93.53 vs. transaction prices of $429–$448.

Breaux executed 2 separate sales totaling 20,000 shares for $8,770,000.00, reducing his holdings by 22.4% to 69,289 shares. Notably, the transaction prices ($429.00 and $448.00, blended average $438.50) are dramatically higher than the current price of $93.53, suggesting this sale occurred months ago and the stock has since declined substantially. Across his prior 5 trades at CVNA, Breaux's 90-day timing record shows 4 of 4 measurable outcomes were well-timed (negative 90d returns ranging from -76.1% to -83.3%), and his cross-ticker track record of 20 prior sells achieved a 100.00% well-timed rate at the 90-day mark with an average 90d return of -78.6%. This filing is significant not as a current market signal but as documentary evidence of a transaction already substantially underwater relative to market: Breaux's sales at $438.50 are now worth approximately $93.53 per share, representing a paper loss on current valuation, yet historically consistent with his demonstrated ability to exit positions before subsequent declines.

Breaux sold 15,000 CVNA shares at $398.00 on 2025-10-01 ($5,970,000 proceeds); holds 81,716 shares post-transaction.

Paul W. Breaux sold 15,000 shares (15.0K shares) at $398.00 for $5,970,000.00 ($6.0M) on 2025-10-01, reducing his stake from 96,716 to 81,716 shares (a -15.5% reduction). The transaction occurred near the 52-week high of $79.08 (the stock now trades at $78.94 current price, -0.2% from that peak). His same-ticker history at CVNA shows five prior sells in August-September 2025, with measurable 30-day outcomes of -79.6%, -79.5%, -80.3%, and -80.2%, indicating a consistent pattern of selling before near-term declines at this ticker. Across his broader cross-ticker open-market history, he has executed 20 prior sells with an average 90-day return of -77.7% and a 90% well-timed rate, suggesting a track record of selling ahead of weakness; however, at CVNA specifically, 0 of 0 prior sells have yet achieved measurable 90-day outcomes, and the company itself posted $4.8B revenue with +26.9% annual growth and 30-day stock momentum of +7.7%, suggesting execution strength that contrasts with the insider's apparent conviction to exit.

Paul W. Breaux sold 15,000 shares of CVNA at $375.00 on 2025-09-09; current price $70.85, down 81.1% from sale price.

Breaux sold 15,000 shares (15.0K shares) at $375.00 on 2025-09-09, reducing his CVNA stake from 98,018 to 83,018 shares (-15.3% vs pre-transaction holdings). The stock has since collapsed to $70.85, representing a decline of 81.1% from the transaction price. His cross-ticker track record shows 20 prior sells with an average 90d return of -77.7% and a 90d well-timed rate of 100.00%, indicating a consistent pattern of exiting before downturns. At CVNA specifically, all 4 measurable same-ticker sells (three from early August, one from June 5) yielded declines of -79.5% to -80.3% over 30 days, with the June 5 sell achieving -79.2% over 90 days. This September 9 sale aligns with a demonstrated insider timing pattern: Breaux appears to have sold near an inflection point, as the stock subsequently experienced a severe drawdown. The current valuation (P/E 41.19) paired with recent quarterly net income of $183.0M and annual revenue growth of +26.9% provides backdrop, but the outsized magnitude of the post-sale decline and the consistency of Breaux's prior successful exits suggest this filing warrants investigation into whether material developments preceded or followed this transaction.

CVNA insider BREAUX sold 15,000 shares for $5.4M at $361.96 avg on 2025-08-05; holds 98.8K post-sale.

Paul W. Breaux executed 2 separate sales totaling 15,000 shares for $5,429,458.08 at a blended average price of $361.96, reducing his stake by 13.2% to 98,792 shares. The transaction prices ($361.91 and $362.69) significantly exceed the current market price of $71.55, indicating these sales occurred at historical peaks relative to today's valuation. Across his 20 prior open-market sells (cross-ticker track record), his average 90-day return after selling was -77.7% with a 100.00% well-timed rate, yet at CVNA specifically his prior 5 sales at this ticker showed no well-timed outcomes at the 90-day mark based on measurable data. This sale pattern—part of a series of 5 CVNA sales in the last 3 months—warrants attention to whether there is a material disclosure gap or operational concern not yet reflected in the current $71.55 price.

Breaux sells 33,000 CVNA shares for $12,260,820.00 across two dates; 5 prior sells at this ticker showed -78.6% to -87.7% 30-day returns.

BREAUX PAUL W. executed 2 separate sales totaling 33,000 shares (33.0K shares) for $12,260,820.00 ($12.3M), reducing his stake from 146,792 to 113,792 shares (-22.5%). His 5 prior trades at CVNA over the past six months all involved sales, with measurable 30-day outcomes ranging from -78.6% to -87.7%, and 90-day measurable outcomes of -79.3% to -79.4%; the 2 prior sales with 90-day data were both well-timed (stock fell after). CVNA's fundamentals show $4.8B quarterly revenue and +26.9% annual growth with a P/E of 41.94; current price is $72.13, down 7.6% from the 52-week high. The pattern of repeated sales by this insider at elevated transaction prices ($371.54 blended average vs $72.13 current) combined with his consistent prior timing success at this ticker merits investor attention.

CVNA insider Breaux Paul W. sells 20,000 shares at $348.00 for $6,960,000; holds 148,340 post-transaction (-11.9%)

Breaux sold 20,000 shares of CVNA at $348.00 on 2025-06-05 for a total value of $6,960,000.00, reducing holdings by 11.9% to 148,340 shares. This transaction occurs at a price materially higher than the current price of $67.98, suggesting the sale was executed during a period of elevated valuations. His prior trading pattern at CVNA shows consistent sell timing: three measurable prior sales at this ticker all generated negative 90-day returns (-87.7%, -79.3%, -79.4%, -86.7%, -80.2%), with all 3 of 3 prior sells well-timed at the 90-day mark. His cross-ticker track record reinforces this pattern—20 prior sells averaged a 90d return of -77.4% with a 100.00% well-timed rate. The company's fundamentals show $4.2B in quarterly revenue, net income of $216.0M, and 26.9% annual revenue growth, with a P/E of 39.52 suggesting elevated valuation multiples.

BREAUX sold 20,000 shares of CVNA at $323.00 on 2025-05-28; 4 of 4 prior CVNA sales were 90-day well-timed (-78.0% to -87.7% post-sale declines).

Paul W. Breaux sold 20,000 shares at $323.00, reducing his holdings from 169.1K to 149.1K shares (−11.8%). His prior four sales at CVNA on 2025-02-10, 2025-02-11 (two tranches), and 2024-10-31 all saw declines within 90 days of −86.7% to −87.7%, indicating a consistent pattern of well-timed exits at this ticker. His cross-ticker track record of 20 prior sells shows a 90d well-timed rate of 100.00% and average 90d returns of −77.4%, reinforcing an established pattern of selling before significant declines. The current stock price of $65.43 sits at the 52-week high (+33.9% in 30d, +40.4% in 90d), raising the question of whether this latest sale at $323.00 (now substantially below current trading levels) represents continuation of that pattern or a divergence.

CVNA insider BREAUX PAUL W. sold 30,000 shares at $298.00 on 2025-05-13; all 5 prior CVNA sales were well-timed (90d average -79.7%).

BREAUX PAUL W. sold 30,000 shares of CARVANA (CVNA) for $8,940,000.00, reducing his holdings by 16.7% from 179,114 to 149,114 shares. His prior trading history at CVNA reveals a striking pattern: all 5 previous sales occurred in 2024–2025, and each preceded material declines, with 90-day returns averaging -79.7% and a 5-of-5 well-timed rate at the 90-day mark. His cross-ticker track record shows 20 prior sells with a 100.00% well-timed rate, suggesting consistent ability to execute sells before subsequent weakness. At $298.00 per share on 2025-05-13, this sale was executed at the upper range of CVNA's 52-week band ($19.79–$61.10), marking a notable exit point relative to the stock's current price of $59.48 and recent 90-day momentum of +4.2%. The company's fundamentals (FY revenue growth +26.9%, net income $216.0M) remain positive, but the insider's sustained pattern of well-timed sales, combined with a high price point for the transaction, warrants careful observation of near-term price action and any material changes in the business outlook.

CVNA insider BREAUX PAUL W. sold 40,000 shares ($10.8M) at $270.54 avg; all 5 prior CVNA sales were well-timed with 90d declines

Paul W. Breaux executed 3 separate sales totaling 40,000 shares for $10,821,442.27 on Feb 10-11, 2025, reducing holdings by 20.7% from 193,240 to 153,240 shares. The timing pattern is striking: his 5 prior trades at CVNA were all well-timed, with each producing 90-day negative returns ranging from -76.5% to -79.7%, establishing a consistent pattern of selling before declines at this ticker. His cross-ticker track record shows a 100.00% well-timed rate on 20 prior sells with -76.8% average 90-day return, though CVNA's performance has improved sharply (stock is +37.8% over 30 days and -1.2% from 52-week high at $54.23, while sale prices averaged $270.54). The sale occurs against the backdrop of deteriorating annual revenue growth (-20.8%) despite positive near-term price momentum, creating a potential clash between insider action and market sentiment that warrants close monitoring of Q1 results.